Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Memantine as Adjunct to Naltrexone for Opioid Dependence
NCT00125515Phase 2Completed
- Sponsor
- New York State Psychiatric Institute
- Start
- Jun 2005
- Primary completion
- Aug 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of memantine in opioid use disorder (OUD) (3 arms), sponsored by New York State Psychiatric Institute. Primary endpoint: Retention in Treatment at 12 weeks. Started Jun 2005; status: completed.
02
Drugs
memantine
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on NCT00125515.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00125515.